When

July 27th, 2017
5:00 p.m. to 7:00 p.m. 

Where:

Bar Louie
150 Gibbs St.
Rockville MD 20850

Add to Calendar

Elite Sponsors


Double Helix Sponsors

 

Contributing Sponsors

PressCommPR


Contact:

The BioBuzz Team
BioBuzz
biobuzzmaryland@gmail.com
410-635-0467

BioBuzz in Rockville with Immunomic Therapeutics

Join BioBuzz and sponsor Immunomic Therapeutics to celebrate the move from allergy to oncology application of their proprietary LAMP-Vax™ technology platform. The celebration will be at Bar Louie in the Rockville Town Center on July 27, 2017 from 5 - 7pm. Only a 5 minute walk from the Rockville Metro, please join us for this exciting event.

 


 

Immunomic is a privately-held, clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases, which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology to cancer immunotherapy

One of ITI’s key application areas in oncology is in glioblastoma GBM. Immunomic recently announced an exclusive licensing agreement that enables Immunomic to combine its nucleic-based immunotherapy platform, LAMP technology, with a patented and proprietary cytomegalovirus (CMV) immunotherapy platform, discovered at Duke University and licensed to Annias. A phase II randomized clinical trial is currently enrolling patients in Florida with newly-diagnosed glioblastoma (GBM) to further explore the combination of LAMP and the CMV platform. The platform has been tested in two Phase I studies. CMV is a virus that has an association with GBM; targeting CMV antigens could be a promising cancer immunotherapy approach for GBM. The two Phase I studies, named ATTAC and ATTAC-GM, showed a median overall survival of 35 and 37 months respectively. While both are single arm studies, median overall survival in GBM is typically reported to be between 15 and 22 months.

For information about ITI and LAMP Technology, visit www.immunomix.com

Throughout the year, BioBuzz hosts a FREE event for like-minded professionals and students to gather and network, reconnect with past coworkers, build stronger relationships and share conversations in a welcoming atmosphere.

THANKS TO THE BIOBUZZ SPONSORS! 

We would like to thank our great sponsors (listed on the left bar) who make the events possible each month. The event is always free and we offer free drinks to the first 50 to 100 who arrive depending on how much we've been sponsored on a given month. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It's a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip  If you're new and haven't yet made it out to an event, then we hope that you'll join us this month and see what all the Buzz is all about. 

Don't forget to also join our BioBuzz LinkedIn group, "like" our Facebook Page, and follow us on Twitter so that you can stay connected to everyone you meet at the event.

INTERESTED IN SPONSORING AN EVENT OR BEING AN ANNUAL SPONSOR?

We wouldn't be able to keep these events free without our sponsors, so contact Chris or Andy for more information.

For more information, please contact us @ biobuzzmaryland@gmail.com  and on twitter @biobuzzmaryland